Detalhe da pesquisa
1.
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).
J Antimicrob Chemother
; 77(3): 758-766, 2022 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34849957
2.
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
J Antimicrob Chemother
; 76(2): 286-291, 2021 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33063117
3.
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
J Antimicrob Chemother
; 75(11): 3373-3378, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32812025
4.
Erratum Erratum to: Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
J Antimicrob Chemother
; 76(6): 1653, 2021 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704468
5.
Brucella pleurisy: An extremely rare complication of brucellosis.
Clin Case Rep
; 10(9): e6366, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36188036
6.
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial.
Iran J Pharm Res
; 20(4): 278-288, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35194446
7.
Evaluating the Effect of Dexmedetomidine on Hemodynamic Status of Patients with Septic Shock Admitted to Intensive Care Unit: A Single-Blind Randomized Controlled Trial.
Iran J Pharm Res
; 19(4): 255-263, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33841540